awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34557885-4EAAFFB0-EDD9-435A-98BE-C1E3FAB9EC06
Q34557885-4EAAFFB0-EDD9-435A-98BE-C1E3FAB9EC06
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34557885-4EAAFFB0-EDD9-435A-98BE-C1E3FAB9EC06
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
P2860
Q34557885-4EAAFFB0-EDD9-435A-98BE-C1E3FAB9EC06
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34557885-4EAAFFB0-EDD9-435A-98BE-C1E3FAB9EC06
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b24cdc07ea378e24de3db0f02c78df46d8a27655
P2860
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.